AstraZeneca (AZN) Stock Rating Reaffirmed by Barclays
A number of other equities analysts have also recently issued reports on the stock. Deutsche Bank upped their price objective on shares of AstraZeneca from GBX 6,000 ($78.40) to GBX 6,400 ($83.63) and gave the stock a buy rating in a research report on Monday, October 8th. Goldman Sachs Group set a GBX 4,080 ($53.31) price objective on shares of AstraZeneca and gave the stock a sell rating in a research report on Wednesday, September 26th. JPMorgan Chase & Co. set a GBX 6,500 ($84.93) price objective on shares of AstraZeneca and gave the stock a buy rating in a research report on Tuesday, September 25th. Citigroup reiterated a buy rating and set a GBX 6,200 ($81.01) price objective on shares of AstraZeneca in a research report on Tuesday, September 25th. Finally, UBS Group reiterated a neutral rating and set a GBX 5,900 ($77.09) price objective on shares of AstraZeneca in a research report on Tuesday, September 25th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have given a buy rating to the company. The stock has a consensus rating of Hold and an average target price of GBX 5,700.70 ($74.49).
AZN stock opened at GBX 5,546 ($72.47) on Tuesday. AstraZeneca has a 1 year low of GBX 4,260 ($55.66) and a 1 year high of GBX 5,520 ($72.13).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Read More: What is the S&P 500 Index?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.